An evaluation of relugolix/estradiol/norethindrone acetate for the treatment of heavy menstrual bleeding associated with uterine fibroids in premenopausal women.
Mohamed AliHsin-Yuan ChenYi-Fen ChiangOsama A BadaryShih Min HsiaAyman Al-HendyPublished in: Expert opinion on pharmacotherapy (2022)
The combination of relugolix/E2/NETA is an encouraging, well-tolerated and noninvasive pharmacological option for UFs patients. Relugolix induced a concentration-dependent decrease in HMB. However, it should be used with hormonal add-back therapy (E2+ NETA) to avoid induced hypoestrogenic side effects, importantly bone mineral density loss. Moreover, symptoms will likely resume shortly after the termination of the relugolix combination administration.
Keyphrases
- bone mineral density
- postmenopausal women
- high glucose
- end stage renal disease
- diabetic rats
- body composition
- ejection fraction
- newly diagnosed
- chronic kidney disease
- pregnancy outcomes
- prognostic factors
- peritoneal dialysis
- oxidative stress
- skeletal muscle
- depressive symptoms
- patient reported outcomes
- adipose tissue
- metabolic syndrome
- physical activity
- combination therapy
- sleep quality
- bone marrow
- stress induced
- estrogen receptor
- early breast cancer